Mark Boer De

Title: Mark Boer De: Innovator in Immunotoxin Therapy

Introduction

Mark Boer De is a notable inventor based in Blaricum, Netherlands. He has made significant contributions to the field of immunotherapy, particularly in the development of immunotoxins for treating various diseases. His innovative approach has the potential to impact the treatment of autoimmune diseases and T-cell malignancies.

Latest Patents

Mark Boer De holds a patent for "Anti-CD40L immunotoxins for the treatment of diseases." This patent describes an immunotoxin molecule that comprises an antibody specific for the human CD40L antigen located on the surface of human cells. The immunotoxin is coupled to a toxin molecule, which, upon binding to the CD40L molecule, results in the killing of the CD40L expressing cell. The toxin molecule is particularly a type-1 ribosome inactivating protein or an active fragment thereof. This immunotoxin can be utilized for treating autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, as well as T-cell malignancies.

Career Highlights

Mark Boer De is associated with Tanox Pharma B.V., where he continues to advance his research and development efforts. His work focuses on creating innovative therapies that leverage the power of immunotoxins to target specific cells involved in disease processes.

Collaborations

Mark Boer De collaborates with Marcel Theodorus Hartog Den, contributing to the advancement of their shared goals in the field of immunotherapy. Their partnership enhances the potential for groundbreaking discoveries in the treatment of complex diseases.

Conclusion

Mark Boer De's contributions to immunotoxin therapy represent a significant advancement in medical science. His innovative patent and ongoing work at Tanox Pharma B.V. highlight his commitment to improving treatment options for patients with autoimmune diseases and T-cell malignancies.